| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Net Income | -183.19 | -90.79 |
| Diluted EPS | -1.55 | -0.81 |
- Net Income YoY
- -101.8%
Key highlights
- Net loss widened by 101.8% year-over-year to $183.19 million in Q3-26
- Diluted loss per share increased to $1.55 compared to $0.81 in Q3-25
- Research and development expenses totaled $432.7 million for the first nine months of 2026
- Company ended the period with $677.6 million in cash and cash equivalents
- Projected quarterly cash burn guided at approximately $100 million moving forward
How the Period Went
Viking Therapeutics reported zero revenue for the third quarter of 2026, maintaining its status as a clinical-stage biotechnology firm with no commercial products. The net loss for the quarter expanded to $183.19 million, a significant increase from the $90.79 million loss recorded during the same period in 2025. This results in a year-over-year net income decline of 101.8%. On a per-share basis, the diluted loss reached $1.55, compared to $0.81 in the prior year. The widening deficit reflects a strategic pivot toward intensive late-stage clinical trials for its primary metabolic and endocrine candidates.
Margins and Profitability
Profitability metrics remain negative as Viking prioritizes R&D over short-term earnings. For the first nine months of 2026, research and development expenses reached $432.7 million, contributing to a total nine-month net loss of $469.5 million. Management guidance provided via MarketBeat on October 28, 2026, anticipates an average quarterly cash burn of roughly $100 million. Despite these losses, the company bolstered its liquidity through public offerings and convertible senior notes, concluding the quarter with $677.6 million in cash. This capital cushion is intended to fund the upcoming high-cost Phase 3 extension studies planned for early 2027.
Business Overview
- Clinical-stage biopharmaceutical developer focused on novel metabolic therapies
- Lead program VK2735 is a dual GLP-1/GIP receptor agonist for obesity treatment
- Developing VK3019, a dual amylin/calcitonin receptor agonist (DACRA)
- Zero order backlog as of September 30, 2026, according to GuruFocus data
- Targeting Phase 1 completion of VK3019 by year-end 2026 per company updates
- Expected initiation of VANQUISH Phase 3 studies for VK2735 in Q1 2027
Financial Context
The current financial results arrive during a period of market volatility for the company. Viking’s market capitalization stands at approximately $2.96 billion, with the stock trading at $25.36. Technical indicators show a Relative Strength Index (RSI) of 40.5, positioning the equity in neutral territory after a quarterly price decline of 27.27%. The 23.22% drop over the last month aligns with broader biotech sector fluctuations as investors weigh high cash burn rates against the long-term potential of weight-loss drug pipelines. The company's recent capital raises have secured the runway necessary to navigate these pre-commercial phases.
Up 5.7% since our story on 29 Oct: $25.36 when we broke it → $26.80 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $25.05 |
|---|---|
| 20 Oct | $26.71 |
| 21 Oct | $26.38 |
| 22 Oct | $25.83 |
| 23 Oct | $24.40 |
| 26 Oct | $24.21 |
| 27 Oct | $24.89 |
| 28 Oct | $25.36 |
| 29 Oct | $26.86 |
| 30 Oct | $27.28 |
| 2 Nov | $26.83 |
| 3 Nov | $26.09 |
| 4 Nov | $27.97 |
| 5 Nov | $25.79 |
| 6 Nov | $26.84 |
| 9 Nov | $28.99 |
| 10 Nov | $28.66 |
| 11 Nov | $28.44 |
| 12 Nov | $27.58 |
| 13 Nov | $29.22 |
| 16 Nov | $26.80 |
Industry Landscape
Viking Therapeutics operates in the competitive metabolic therapeutic space, currently dominated by established GLP-1 providers. While larger peers report surging commercial sales, Viking competes on next-generation delivery and dual-agonist efficacy. According to company announcements via StockTitan, the expected Q1 2027 initiation of Phase 3 studies for subcutaneous VK2735 will be a critical sector event. Industry demand for obesity treatments remains high, but clinical-stage firms like Viking face pressure to deliver differentiated data in a crowded field of amylin and GIP receptor agonists. The completion of the VK3019 study by year-end will be an important indicator of pipeline breadth.
| Date | Announcement | Amount |
|---|---|---|
| 28 Oct 2026 | Q3 2026 net lossSource: prnewswire.com | $183.2 Million |
| 29 Jul 2026 | Q2 2026 net lossSource: prnewswire.com | $128.0 Million |
| 29 Apr 2026 | Q1 2026 net lossSource: prnewswire.com | $158.3 Million |
| 11 Feb 2026 | Q4 2025 net lossSource: prnewswire.com | $157.7 Million |
| 22 Oct 2025 | Q3 2025 net lossSource: investing.com | $90.8 Million |
| 23 Jul 2025 | Q2 2025 net lossSource: SEC filing | $65.6 Million |
| Share price | $25.36 |
|---|---|
| Market cap | $3.0B |
| 1-month price change | -23.22% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Viking Therapeutics, Inc. announcing its third quarter 2026 financial results.
Track Viking Therapeutics, Inc. live
Get the next Viking Therapeutics, Inc. SEC filing seconds after it lands.



